On 23 October 2009, British Swimmer Heather Frederiksen was subject to an in-competition doping control test at the 2009 IPC Swimming European Championships. An adverse analytical finding of Salbutamol (Class S3) with an concentration of more than 1000 ng/mL was found in the athlete’s sample. A Therapeutic Use Exemption (TUE) granted for the use of Salbutamol did not justify this concentration. Consequently, under the concentration reported, Salbutamol is a substance prohibited under the 2009 WADC Prohibited List. Furthermore, upon request of the athlete, the B Sample was analyzed on 30 November 2009. The results of the B Sample analysis confirmed the results of the A Sample. In accordance with the provisions of the 2009 WADC Prohibited List, Ms. Frederiksen underwent a pharmacokinetic study to demonstrate that the level of prohibited substance in her sample arose of a required therapeutic use.
Upon receipt of the results of this study, a hearing was convened on 4 May 2010. As a result of this hearing, the IPC imposed a sanction of six months ineligibility, considering Article 10.2 and 10.4 of the IPC Anti-Doping Code from 23 October 2009, the day of the anti-doping rule violation.
In accordance with IPC Anti-Doping Code (Article 9 & 10.1), all individual results obtained from 23 October 2009 onwards shall be disqualified including the forfeit of any medals, points and prizes.
As a signatory of the World Anti-Doping Code (WADC), the IPC remains committed to a doping free sporting environment at all levels. The IPC, together with the International Federations and the National Paralympic Committees, established the IPC Anti-Doping Code to prevent in the spirit of fair play, doping in sport for athletes with a disability and in conformity with the general principles of the World Anti-Doping Code.